Defining and treating high-grade B-cell lymphoma, NOS

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently defined category for aggressive B-cell lymphomas.
• This group includes tumors with Burkitt-like or blastoid morphology lacking double-hit cytogenetics and not fitting other subtypes.
• HGBL, NOS, is rare, heterogeneous, often presents with germinal center B-cell phenotype, and may feature MYC rearrangements.

Purpose of the Study:

• To review the current clinicopathologic understanding of HGBL, NOS.
• To discuss existing data on prognosis and treatment for HGBL, NOS.
• To explore potential future classifications using molecular diagnostics.

Main Methods:

• Review of existing literature on HGBL, NOS.
• Analysis of gene expression profiling (GEP) data.
• Discussion of current diagnostic and treatment paradigms.

Main Results:

• Recent GEP studies suggest up to 15% of diffuse large B-cell lymphomas may fit an HGBL-like signature.
• Optimal treatment for HGBL, NOS, remains poorly defined due to rarity and diagnostic inconsistencies.
• Early-stage disease may respond to R-CHOP, while advanced stages might benefit from intensified regimens with CNS prophylaxis.

Conclusions:

• HGBL, NOS, is a challenging entity requiring improved classification for better patient outcomes.
• Molecular criteria, such as GEP and genomic profiling, hold promise for refining HGBL, NOS, diagnosis.
• Future research should focus on developing HGBL-specific trials based on enhanced molecular classification.